Vendor News

Vendor News

S Zhaveri Pharmakem in JV with JRS Pharma

S Zhaveri Pharmakem (SZPPL) and Rettenmaier Asia Holding GmbH have entered into a joint venture agreement, concerning mainly world-wide co-operation in pharmaceutical and nutraceutical contract research and development work. According to a company note, Rettenmaier Asia Holding GmbH with headquarters in Rosenberg, Germany is a group company of the JRS Pharma group. It is leading the world in excipients with innovative products, patented technologies and technical expertise for pharmaceutical and nutritional industries worldwide.

S Zhaveri Pharmakem is a well-established distributor, representing worldwide pharmaceutical excipient manufacturers catering to the Indian market. S Zhaveri not only represents JRS but also other principals such as Evonik (Degussa), Vertellus, (Morflex),Gelita, PPG Industries, Ranson, Frutarom, Peter Greven, B K Giulini, Astatech etc. Its headquarter is based in Mumbai, India. In the recently S Zhaveri has developed a new business line in the area of contract R&D for formulations.

According to J O Rettenmaier, President of JRS, “This joint venture is just a logical consequence in our efforts to strengthen our one stop philosophy we have continuously developed for the leading pharmaceutical companies. Not only that; we can offer the most comprehensive range of pharma-ceutical excipients with high quality standards and at reasonable cost but we are now also in a position to accompany the pharma companies from the first steps in the product development to the production and marketing of the drugs to the benefit of our customers. With our decision for SZPPL we have chosen a partner with whom we already had successful business relations since more than one decade, located in one of the world centres of pharma industry with high technical capabilities and high cost competitiveness.”

“We are extremely pleased with our alliance with JRS, a leader in the distribution of excipients” said Uma Javeri, President, SZPPL. “The joint venture will be beneficial for both companies and also form a basis for future collaborative activities.

The co-operation opens up for us the already well established and recognised JRS sales network with its sales offices in USA, Brazil, Mexico, Germany, UK, France, Czech Republic, Benelux, Poland, Italy, Austria, Japan, Spain, Finland, Russia and China and also the JRS worldwide distributor network. Along with this, the access routes already established by JRS to the R&D departments of the world leading pharmaceutical companies and our own distribution channels the JV should boost the business opportunities for our offered R&D service.”

We also appreciate the access we gain to the advanced technical know how of JRS in the area of R&D, technical service, manufacturing process engineering and quality assurance which will have a further positive impact on our productivity and quality, Javeri added. The company note also indicated that the JV will further lead to the setting up of a world class contract research centre with a pilot plant and manufacturing facility on the outskirts of Mumbai. This facility will adhere to all the regulatory requirements that will support our customers to register and market their product efficiently.